RxDoctor Payments Data

Eric Dessner, MD

Ophthalmology · Brooklyn, NYNPI 1861686545

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 47 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$446
  • Amgen$254
  • Mallinckrodt Enterprises LLC$140
  • Lilly USA, LLC$123
  • Aerie Pharmaceuticals, Inc.$59
  • Genentech USA, Inc.$50
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$1,16998%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$108,786
Medicare patients
248
Services billed
1,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$53,793
RhopressaNetarsudil Mesylate113$42,829
LumiganBimatoprost89$24,812
CombiganBrimonidine Tartrate/Timolol94$23,260
Latanoprost2,073$12,079
SimbrinzaBrinzolamide/Brimonidine Tart58$11,878
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol106$7,632
Prednisolone Acetate263$7,586
Brimonidine Tartrate500$6,987
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat433$6,256
RocklatanNetarsudil Mesylat/Latanoprost17$6,065
Brinzolamide35$3,799
Ketorolac Tromethamine156$2,505
Timolol Maleate90$1,821
Travoprost13$1,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$59$48,894130 claims
AlconSimbrinza$446$11,87858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →